Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice

Barati, Nastaran; Razazan, Atefeh; Nicastro, Jessica; Slavcev, Roderick A.; Arab, Atefeh; Mosaffa, Fatemeh; Nikpoor, Amin Reza; Badiee, Ali; Jaafari, Mahmoud Reza; Behravan, Javad

doi:10.1016/j.canlet.2018.03.030

Cited by 25 publications

(19 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Induction of modified phage nanoparticles [λF7 (gpD::AE37)] induce the eukaryotic immune system for the production of CD8 + T cells, CD4 + IL‐4, and IFNᵧ and facilitate MHC II molecules. The chimeric phage particles showed immunogenicity along with targeted antitumor activity . Similarly, several other studies have been carried out using genome editing techniques for targeted delivery of drugs, genes and proteins to mammalian cells …”

Section: Why Phage Therapy?mentioning

confidence: 92%

“…Phage display has a role in delivery of therapeutic agents including genes, vaccines and drugs. Some other applications of phage display include epitope identification, targeting the eukaryotic cells, nanomaterials design, cancer research and therapy, bioimaging and a lot more . A number of restrictions associated with phages can be minimized by phage genome editing .…”

Section: Why Phage Therapy?mentioning

confidence: 99%

See 1 more Smart Citation

The dawn of phage therapy

Rehman

Ali

Khan

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

Bacteriophages or phages, being the most abundant entities on earth, represent a potential solution to a diverse range of problems. Phages are successful antibacterial agents whose use in therapeutics was hindered by the discovery of antibiotics. Eventually, because of the development and spread of antibiotic resistance among most bacterial species, interest in phage as therapeutic entities has returned, because their noninfectious nature to humans should make them safe for human nanomedicine.This review highlights the most recent advances and progress in phage therapy and bacterial hosts against which phage research is currently being conducted with respect to food, human, and marine pathogens. Bacterial immunity against phages and tactics of phage revenge to defeat bacterial defense systems are also summarized.We have also discussed approved phage-based products (whole phage-based products and phage proteins) and shed light on their influence on the eukaryotic host with respect to host safety and induction of immune response against phage preparations.Moreover, creation of phages with desirable qualities and their uses in cancer treatment, vaccine production, and other therapies are also reviewed to bring together evidence from the scientific literature about the potentials and possible utility of phage and phage encoded proteins in the field of therapeutics and industrial biotechnology.

show abstract

Section: Why Phage Therapy?mentioning

confidence: 92%

Section: Why Phage Therapy?mentioning

confidence: 99%

The dawn of phage therapy

Rehman

Ali

Khan

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…In addition, we have shown the anti-tumor activity of GP2 and AE37 peptides displayed on phage λF7 (gpD::GP2 and gpD::AE37) in BALB/c mice with the TUBO tumor. The prophylactic and therapeutic activities against TUBO tumor model in mice indicated effective immunogenicity of the designed phage display systems (Barati et al 2018;Razazan et al 2019).…”

Section: Strategies To Improve Immunogenicity Of Peptide Vaccinesmentioning

confidence: 99%

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

Arab

Yazdian‐Robati

Behravan

2020

Arch. Immunol. Ther. Exp.

Self Cite

View full text Add to dashboard Cite

Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically improved by understanding of the immune regulatory mechanisms of tumor microenvironment. Passive immunotherapy utilizing recombinant monoclonal antibodies (mAbs), particularly trastuzumab and pertuzumab has proved to be an effective strategy in HER2-positive breast cancer treatment. However, resistance to mAb therapy and relapse of disease are still considered important challenges in clinical practice. There are increasing reports on the induction of cellular and humoral immune responses in HER2-positive breast cancer patients. More recently, increasing efforts are focused on using HER2-derived peptide vaccines for active immunotherapy. Here, we discuss the development of various HER2-derived vaccines tested in animal models and human clinical trials. Different formulations and strategies to improve immunogenicity of the antigens in animal studies are also discussed. Furthermore, other immunotherapeutic approaches to HER2 breast cancer including, CTLA-4 inhibitors, immune checkpoint inhibitors, anti PD-1/PD-L1 antibodies are presented.

show abstract

“…As mentioned earlier, ligand density influences the type of immune response that develops and is of particular importance to response to cancer therapeutics. 82 Phage display vaccines have been targeted toward cancers such as breast, 83,84 liver, 85 and lung, 86 and some examples are discussed below in detail.…”

Section: Phage As a Tumor Antigen Display Toolmentioning

confidence: 99%

Phage display as a tool for vaccine and immunotherapy development

Hess

Jewell

2019

Bioengineering & Transla Med

View full text Add to dashboard Cite

Bacteriophages, or phages, are viruses that specifically infect bacteria and coopt the cellular machinery to create more phage proteins, eventually resulting in the release of new phage particles. Phages are heavily utilized in bioengineering for applications ranging from tissue engineering scaffolds to immune signal delivery. Of specific interest to vaccines and immunotherapies, phages have demonstrated an ability to activate both the innate and adaptive immune systems. The genome of these viral particles can be harnessed for DNA vaccination, or the surface proteins can be exploited for antigen display. More specifically, genes that encode an antigen of interest can be spliced into the phage genome, allowing antigenic proteins or peptides to be displayed by fusion to phage capsid proteins. Phages therefore present antigens to immune cells in a highly ordered and repetitive manner. This review discusses the use of phage with adjuvanting activity as antigen delivery vehicles for vaccination against infectious disease and cancer. K E Y W O R D S bacteriophage, biomaterials, drug delivery, immunology, nanotechnology, phage display, vaccine 1 | INTRODUCTION Bacteriophages, or phages, are prokaryotic viruses that specifically infect bacteria, and are the most abundant life form on earth. 1 Phages were first discovered in the early 20th century and noted for their antibacterial activity. The practice of administering phages (i.e., phage therapy) to patients suffering from bacterial infections began shortly after their discovery, but was controversial largely due to lack of mechanistic knowledge and variable success rates. In fact, the treatment was largely abandoned upon the discovery of antibiotics. 2 Research in this field was reenergized, however, following the development of phage display systems in 1985. 3 George Smith, a chemist at the University of Missouri, demonstrated fusion of peptides to the outer (i.e., capsid) proteins of phages enabling surface display. This work, for which Smith shared a Nobel Prize in 2018, laid the ground work for affinity selection, epitope mapping, and antibody discovery. Since this time, phages have been an important tool for the bioengineering field, exploited for a range of applications including theranostics, 4 batteries, 5,6 drug delivery, 7 and vaccine development. 1Phages are one of many nanotechnologies being investigated for these applications. This review will focus on the advantages that phages provide to the nanomedicine field, specifically vaccination and immunotherapy. Nanomedicine ranges from diagnostics to treatments and relies on the fields of biomedical and chemical engineering,

show abstract

Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice

Cited by 25 publications

References 44 publications

The dawn of phage therapy

The dawn of phage therapy

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

Phage display as a tool for vaccine and immunotherapy development

Contact Info

Product

Resources

About